Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it ...

Guardant Health (NASDAQ:GH), a $5.49 billion market cap healthcare company, announced a significant step in its financial strategy, reaching an agreement to exchange a portion of its convertible notes ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange ...

Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year.

Craig-Hallum analyst William Bonello maintained a Buy rating on Guardant Health (GH – Research Report) today. The company’s shares closed ...

Guardant Health (GH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock ...

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on DraftKings (DKNG – Research Report). The company’s ...